Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IgM ATAC
- Development stage
- Preclinical
- Lead developer
- Avilar Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
IgM ATAC is an oral heterobifunctional protein degrader being developed by Avilar Therapeutics for the treatment of Anti-MAG neuropathy. It is part of the company's Antibody-Targeted Autologous Cell (ATAC) platform, which utilizes the asialoglycoprotein receptor (ASGPR) expressed on hepatocytes to facilitate the endocytosis and subsequent lysosomal degradation of extracellular proteins. IgM ATAC is specifically designed to target and degrade pathogenic Immunoglobulin M (IgM) autoantibodies, which are the primary drivers of demyelination and nerve damage in Anti-MAG neuropathy. By lowering the levels of these circulating autoantibodies, the therapy aims to provide a disease-modifying treatment for patients suffering from this chronic autoimmune condition.
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)IgM (Immunoglobulin M)
Beyond the preview
Go deeper on IgM ATAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IgM ATAC.